問卷

TPIDB > Study Site

Study Site



National Taiwan University Hospital

  • 2,600

    Total Beds

  • 1,008

    Total Doctors

  • linsinjie@ntuh.gov.tw
  • 100Taipei CityJhong Jheng7 Chung Shan S. Rd.,Zhongzheng

篩選

List

3348Cases

2023-08-11 - 2023-10-18

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-10-30 - 2022-10-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-01-19 - 2027-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting2Sites

Recruiting7Sites

2023-01-10 - 2035-06-15

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity
  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2019-08-20 - 2022-03-01

Phase III

PIONEER 12 Multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin
  • Condition/Disease

    Diabetes Mellitus, Type 2

  • Test Drug

    Semaglutide Tablets

Participate Sites
4Sites

Terminated4Sites

2019-08-01 - 2022-03-31

Phase III

PIONEER 11 Multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only
  • Condition/Disease

    type 2 diabetes mellitus

  • Test Drug

    Semaglutide Tablets

Participate Sites
3Sites

Terminated3Sites

2006-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2005-05-01 - 2006-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-02-01 - 2009-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites